Arcturus Therapeutics Holdings (ARCT) Depreciation & Amortization (CF) (2018 - 2026)

Arcturus Therapeutics Holdings (ARCT) has 9 years of Depreciation & Amortization (CF) data on file, last reported at $658000.0 in Q1 2026.

• Quarterly Depreciation & Amortization (CF) fell 17.85% year-over-year to $658000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.0 million (down 12.29% YoY) and the FY2025 annual result came in at $3.0 million, down 13.57% from the prior year.
• Depreciation & Amortization (CF) eased to $658000.0 in Q1 2026, from $725000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $900000.0 in Q1 2024 to a low of $224000.0 in Q1 2022.
• A 5-year average of $689705.9 and a median of $800000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) decreased 27.04% — and 2023, when it soared 158.04%.
• Tracing ARCT's Depreciation & Amortization (CF) over 5 years: stood at $524000.0 in 2022, then soared by 55.53% to $815000.0 in 2023, then fell by 1.84% to $800000.0 in 2024, then slipped by 9.38% to $725000.0 in 2025, then dropped by 9.24% to $658000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $658000.0 (Q1 2026), $725000.0 (Q4 2025), and $800000.0 (Q3 2025), per Business Quant data.